Baseline characteristics according to genotype of FOXO3A SNP rs12212067 in patients with non-viral cardiomyopathy
| Baseline characteristics FOXO3A SNP rs12212067 in V- DCMi | ||||||||||
| Variable n = 221 | All patients | SNP carrier Mm n=45, 20.4% | No SNP MM n=176, 79.6% | P value | ||||||
| Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | |||||
| Age (years) | 50.9 | 48.9 to 52.9 | 50.2 | 45.9 to 54.6 | 51.1 | 48.9 to 53.3 | 0.547 | |||
| Sex m/f (%) | 74.7/25.3 | 77.8/22.2 | 73.9/26.1 | 0.59 | ||||||
| Echocardiographic parameters | ||||||||||
| LVEF (%) | 35.5 | 33.5 to 37.4 | 39.2 | 34.3 to 44.0 | 34.5 | 32.4 to 36.5 | 0.083 | |||
| LVEDD (mm) | 59.8 | 58.5 to 61.2 | 58.9 | 56.3 to 61.5 | 60.1 | 58.6 to 61.6 | 0.702 | |||
| LVEDV (mL) | 184.4 | 175.2 to 193.5 | 176.5 | 159.8 to 193.1 | 186.3 | 175.6 to 197.1 | 0.702 | |||
| LVEDVI (mL/m²) | 93.3 | 88.5 to 98.2 | 89 | 80.2 to 97.8 | 94.5 | 88.8 to 100.2 | 0.841 | |||
| LA (mm) | 44.8 | 43.4 to 46.2 | 45.6 | 42.0 to 49.2 | 44.6 | 43.1 to 46.2 | 0.595 | |||
| IVSd (mm) | 11.5 | 11.1 to 11.9 | 12.3 | 11.1 to 13.4 | 11.3 | 10.9 to 11.7 | 0.18 | |||
| LVPWs (mm) | 10.8 | 10.5 to 11.1 | 11.4 | 10.5 to 12.3 | 10.7 | 10.4 to 11.0 | 0.185 | |||
| FS (%) | 22.2 | 20.4 to 24.0 | 25.2 | 20.7 to 29.8 | 21.3 | 19.4 to 23.2 | 0.104 | |||
| Clinical parameters | ||||||||||
| Dyspnoea (%) | 81 | 15 | 66 | 0.138 | ||||||
| NYHA class I (%) | 19 | 6 | 13 | 0.138 | ||||||
| NYHA class II (%) | 24 | 5 | 19 | 0.616 | ||||||
| NYHA class III (%) | 39 | 6 | 33 | 0.129 | ||||||
| NYHA class IV (%) | 18 | 4 | 14 | 0.896 | ||||||
| NYHA class I–IV total (n) | 197 | 41 | 156 | 0.151 | ||||||
| Angina pectoris (%) | 16 | 5 | 11 | 0.598 | ||||||
| CCS class 0 (%) | 84 | 19 | 65 | 0.598 | ||||||
| CCS class I (%) | 5 | 2 | 3 | 0.243 | ||||||
| CCS class II (%) | 2 | 2 | 0 | 0.058 | ||||||
| CCS class III (%) | 2 | 1 | 1 | 0.396 | ||||||
| CCS class IV (%) | 8 | 0 | 8 | 0.061 | ||||||
| CCS class 0–IV (n) | 133 | 32 | 101 | 0.505 | ||||||
| RR sys (mm Hg) | 121.9 | 118.8 to 125.1 | 123.4 | 117.6 to 129.2 | 121.6 | 118.0 to 125.3 | 0.356 | |||
| RR dia (mm Hg) | 75.6 | 73.6 to 77.6 | 76.7 | 73.0 to 80.3 | 75.3 | 73.0 to 77.7 | 0.378 | |||
| Pulse (n/min) | 80.9 | 77.9 to 83.9 | 78.4 | 73.5 to 83.2 | 81.6 | 78.0 to 85.2 | 0.774 | |||
| EMB analysis: Inflammatory infiltrates | ||||||||||
| CD3+ (mm²) | 14 | 11.9 to 16.2 | 14.7 | 8.6 to 20.8 | 13.9 | 11.7 to 16.1 | 0.855 | |||
| CD45+ (mm²) | 32.5 | 28.1 to 36.9 | 40.1 | 25.3 to 54.8 | 30.4 | 26.4 to 34.4 | 0.306 | |||
| Perforin+ (mm²) | 2.1 | 1.7 to 2.6 | 1.9 | 0.8 to 3.0 | 2.2 | 1.7 to 2.7 | 0.636 | |||
| Mac-1+ (mm²) | 52.3 | 46.1 to 58.5 | 59.2 | 40.9 to 77.5 | 50.5 | 44.1 to 56.8 | 0.088 | |||
| HLA-1+/AF (%) | 7.9 | 7.4 to 8.4 | 8.2 | 6.6 to 9.8 | 7.9 | 7.4 to 8.3 | 0.578 | |||
| CD106+/AF (%) | 0.08 | 0.07 to 0.09 | 0.09 | 0.07 to 0.11 | 0.07 | 0.06 to 0.08 | 0.086 | |||
| LFA-1+ (mm2) | 33.2 | 27.6 to 38.8 | 41.6 | 20.0–63.2 | 30.9 | 26.5 to 35.3 | 0.584 | |||
| CD54+/AF (%) | 2.7 | 2.5 to 2.8 | 2.9 | 2.5 to 3.3 | 2.6 | 2.4 to 2.8 | 0.222 | |||
| Cardiomyocyte diameter (μm) | 21.1 | 20.5 to 21.7 | 21.4 | 20.0 to 22.7 | 21 | 20.3 to 21.8 | 0.619 | |||
| Inflammatory markers in blood | ||||||||||
| Leucocytes (cells/μL) | 8.1 | 7.6 to 8.5 | 7.8 | 7.0 to 8.6 | 8.1 | 7.6 to 8.7 | 0.655 | |||
| CRP (mg/dL) | 2 | 1.4 to 2.7 | 1 | 0.4 to 1.6 | 2.3 | 1.5 to 3.1 | 0.308 | |||
| Comorbidity charackteristics | ||||||||||
| CCI score adjusted for age | 3.1 | 2.8 to 3.4 | 2.9 | 2.3 to 3.4 | 3.2 | 2.8 to 3.5 | 0.545 | |||
| Predicted 10-year survival (%) | 66.6 | 61.9 to 71.4 | 71.2 | 61.5 to 80.9 | 65.5 | 60.0 to 70.9 | 0.514 | |||
Data are expressed as mean with 95% CI.
CCI, Charlson comorbidity index; CRP, C- reactive protein; DCMi, dilated inflammatory cardiomyopathy; EMB, endomyocardial biopsy; 10 FS, fractional shortening; IVSd, intraventricular septum diameter (diastole); LA, left atrium; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic diameter volume; LVEDVI, left ventricular end-diastolic diameter volume index; LVEF, left ventricular ejection fraction; LVPWs, left ventricular posterior wall (systole); MM, major; Mm, heterozygote; NYHA, New York Heart Association; RR, blood pressure; SNP, single-nucleotide polymorphism; V- DCMi, patients with non-viral cardiomyopathy.